Agenus Inc. (NASDAQ: AGEN) reported first quarter 2026 financial results, showing $4.6 million in pre-commercial product revenue from its botensilimab ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE